Kura Oncology Inc (KURA)
20.63
+0.04
(+0.19%)
USD |
NASDAQ |
May 03, 16:00
20.63
0.00 (0.00%)
Pre-Market: 20:00
Kura Oncology Total Liabilities (Quarterly): 48.82M for March 31, 2024
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 48.82M |
December 31, 2023 | 51.66M |
September 30, 2023 | 43.83M |
June 30, 2023 | 35.06M |
March 31, 2023 | 30.79M |
December 31, 2022 | 36.03M |
September 30, 2022 | 28.37M |
June 30, 2022 | 21.93M |
March 31, 2022 | 22.34M |
December 31, 2021 | 27.44M |
September 30, 2021 | 27.38M |
June 30, 2021 | 26.34M |
March 31, 2021 | 34.28M |
December 31, 2020 | 36.31M |
September 30, 2020 | 33.07M |
June 30, 2020 | 30.63M |
March 31, 2020 | 23.26M |
December 31, 2019 | 23.19M |
Date | Value |
---|---|
September 30, 2019 | 21.02M |
June 30, 2019 | 19.10M |
March 31, 2019 | 20.05M |
December 31, 2018 | 21.39M |
September 30, 2018 | 16.89M |
June 30, 2018 | 17.23M |
March 31, 2018 | 16.66M |
December 31, 2017 | 15.99M |
September 30, 2017 | 13.92M |
June 30, 2017 | 12.21M |
March 31, 2017 | 11.68M |
December 31, 2016 | 12.94M |
September 30, 2016 | 12.64M |
June 30, 2016 | 11.70M |
March 31, 2016 | 4.316M |
December 31, 2015 | 5.156M |
September 30, 2015 | 5.043M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
19.10M
Minimum
Jun 2019
51.66M
Maximum
Dec 2023
31.04M
Average
29.50M
Median
Total Liabilities (Quarterly) Benchmarks
AIM ImmunoTech Inc | 9.147M |
Perspective Therapeutics Inc | 22.71M |
Protalix BioTherapeutics Inc | 50.86M |
Electromed Inc | 6.622M |
Armata Pharmaceuticals Inc | 130.43M |
Total Liabilities (Quarterly) Related Metrics
Total Assets (Quarterly) | 553.91M |
Shareholders Equity (Quarterly) | 505.08M |